Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

GE Extends Strategic Relationship With Australian-based Nanosonics to Expand Healthcare Innovation Globally



  GE Extends Strategic Relationship With Australian-based Nanosonics to Expand
  Healthcare Innovation Globally

  * GE’s healthymagination Fund invests $7.5 million to drive ultrasound
    disinfection innovation and product development.
  * Accelerates GE Healthcare’s commitment to address patient safety and
    infection control, a $10.3 billion global market growing at 12% CAGR.

Business Wire

SYDNEY -- June 25, 2012

GE [NYSE: GE] today announced a $7.5 million investment in Australian-based
Nanosonics Limited [ASX: NAN] - a leader in the development of innovative
technology for infection control - to further develop and distribute Trophon
EPR, an ultrasound transducer disinfecting system. The investment is being
made through the GE healthymagination Fund, which makes investments in
healthcare technology companies.

“Hospital acquired infections (HAIs) have increased by 36% in the last 20
years and are consuming more healthcare dollars each year,” said Ron
Weinberger, Managing Director of Nanosonics. “In the ultrasound market,
sonographers see over ten patients a day, resulting in an increased need to
disinfect the ultrasound transducer thoroughly between patients. Nanosonics
has developed Trophon EPR, an innovative ultrasound disinfecting system, that
we feel will significantly lower the risk of HAIs among patients.”

Realizing there was a significant need to address transducer disinfection, GE
Healthcare worked with Australian-based Nanosonics in 2006 to support the
validation of the Trophon EPR. After a few years of extensive research,
development and testing, Trophon received FDA approval in 2011 and was sold to
customers in the US, Canada and Europe. Currently, Trophon is installed at
more than 800 customer sites globally.

“When patients get scanned, they deserve full assurance that the equipment
being used is safe and clean. The Trophon technology achieves that - and
revolutionizes infection control processes as we know it,” said Dr Weinberger.

Specifically, the technology results in:

  * Improved Turnaround Time: The system takes a total of 7 minutes to
    disinfect between patients. This is about half the time compared to
    traditional disinfection techniques, meaning more patients can get scanned
    in a day.
  * Convenience: Trophon can be placed in the same room as the ultrasound
    machine. Other methods require a separate disinfection room due to the
    powerful chemicals that are used.
  * Environmentally Friendly Solution: The system breaks down residual
    disinfectants into water and oxygen which is safer for the environment,
    patient and sonographer.

“Nanosonics has built an attractive business with an extraordinary product,”
said Michael Ackland, President and CEO of GE Healthcare Australia & New
Zealand. “We believe the continued collaboration with Nanosonics will help
serve our healthcare customers better, complementing GE’s suite of ultrasound
technologies, software and services. By expanding our sales footprint in Japan
as well as in the existing locations such as the US, Canada and Europe, GE
will help customers improve their overall quality in ultrasound processes.

“We’re delighted to be investing in a great Australian company and to help
bring this unique technology to the rest of the world,” said Mr Ackland.

About GE

GE (NYSE: GE) works on things that matter. The best people and the best
technologies taking on the toughest challenges. Finding solutions in energy,
health and home, transportation and finance. Building, powering, moving and
curing the world. Not just imagining. Doing. GE works. For more information,
visit the company's website at www.ge.com. Follow GE on twitter @GEaustralia

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that
are shaping a new age of patient care. Our broad expertise in medical imaging
and information technologies, medical diagnostics, patient monitoring systems,
drug discovery, biopharmaceutical manufacturing technologies, performance
improvement and performance solutions services help our customers to deliver
better care to more people around the world at a lower cost. In addition, we
partner with healthcare leaders, striving to leverage the global policy change
necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on
our journey as we continuously develop innovations focused on reducing costs,
increasing access and improving quality around the world. Headquartered in the
United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE:
GE). Worldwide, GE Healthcare employees are committed to serving healthcare
professionals and their patients in more than 100 countries. For more
information about GE Healthcare, visit our website at www.gehealthcare.com

About GE Capital

GE Capital Australia and New Zealand is a specialist financial services
provider and part of the global GE Capital business, which operates in 55
countries around the world. With 4,300 employees and over $16 billion in
assets locally, GE Capital offers unique financial solutions such as fleet and
equipment finance, personal loans, retailer solutions and credit cards,
corporate finance, inventory finance and insurance services. For more
information visit www.gecapital.com.au. Follow GE Capital on Twitter
@GECapitalAus

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products
designed to reduce the spread of infection. The Company owns intellectual
property relating to a unique disinfection and sterilisation technology which
can be suited to a variety of markets. For more information visit
www.nanosonics.com.au

Caution Concerning Forward-Looking Statements:

This document contains “forward-looking statements” – that is, statements
related to future, not past, events. In this context, forward-looking
statements often address our expected future business and financial
performance and financial condition, and often contain words such as “expect,”
“anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.”
Forward-looking statements by their nature address matters that are, to
different degrees, uncertain. For us, particular uncertainties that could
cause our actual results to be materially different than those expressed in
our forward-looking statements include: current economic and financial
conditions, including volatility in interest and exchange rates, commodity and
equity prices and the value of financial assets; potential market disruptions
or other impacts arising in the United States or Europe from developments in
the European sovereign debt situation; the impact of conditions in the
financial and credit markets on the availability and cost of General Electric
Capital Corporation’s (GECC) funding and on our ability to reduce GECC’s asset
levels as planned; the impact of conditions in the housing market and
unemployment rates on the level of commercial and consumer credit defaults;
changes in Japanese consumer behavior that may affect our estimates of
liability for excess interest refund claims (Grey Zone); pending and
threatened litigation against WMC, including increased activity by
securitization trustees; our ability to maintain our current credit rating and
the impact on our funding costs and competitive position if we do not do so;
the adequacy of our cash flow and earnings and other conditions which may
affect our ability to pay our quarterly dividend at the planned level; our
plan to resume GECC dividends, which is subject to Federal Reserve review; the
level of demand and financial performance of the major industries we serve,
including, without limitation, air and rail transportation, energy generation,
real estate and healthcare; the impact of regulation and regulatory,
investigative and legal proceedings and legal compliance risks, including the
impact of financial services regulation; strategic actions, including
acquisitions, joint ventures and dispositions and our success in completing
announced transactions and integrating acquired businesses; the impact of
potential information technology or data security breaches; and numerous other
matters of national, regional and global scale, including those of a
political, economic, business and competitive nature. These uncertainties may
cause our actual future results to be materially different than those
expressed in our forward-looking statements. We do not undertake to update our
forward-looking statements.

Contact:

GE Healthcare, Australia & New Zealand
Kym Robins, +61 2 9846 4807
Communications Leader
kym.robins@ge.com
or
GE Healthcare Global Services
Britta Barrett, +1-203-400-1892
Communications Director
Britta.Barrett@ge.com
or
GE Corporate
Megan Parker, +1-203-373-2020
Healthymagination Communications Director
Megan.Parker@ge.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement